Piper Hannah G, Coughlin Laura A, Hussain Sarah, Nguyen Van, Channabasappa Nandini, Koh Andrew Y
Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada.
Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas.
J Surg Res. 2020 Jul;251:112-118. doi: 10.1016/j.jss.2020.01.024. Epub 2020 Mar 2.
Children with short bowel syndrome (SBS) frequently struggle with malabsorption and poor growth. The intestinal microbiota plays an important role in gut function, and children with SBS have known deficiencies in some commensal gut microbes. One strategy to enhance the gut microbiota is by taking probiotics. However, the efficacy of this approach is not well established. We hypothesized that probiotic supplementation would result in increased levels of the supplemented bacteria and improved growth.
Children with SBS who had weaned from parenteral nutrition but with suboptimal growth were randomized to receive probiotics (Lactobacillus rhamnosus and Lactobacillus johnsonii) or placebo daily for 2 mo. The gut microbiota from monthly stool samples were compared between groups using 16S ribosomal ribonucleic acid sequencing and quantitative polymerase chain reaction. Growth between groups was also compared. Statistical analysis was completed using Mann-Whitney, Kruskal-Wallis, and chi-square tests as appropriate.
Eighteen children with SBS completed the study (n = 9 per group). There were no significant changes to the major bacterial families in either group. Median relative abundance of Lactobacillus did not differ between groups at baseline or at the end of the study (7.67 versus 13.23, P = 0.523 and 1.93 versus 15.8, P = 0.161). Median z scores for weight and length did not differ between groups at the beginning or end of the study.
The efficacy of daily probiotic use in children with intestinal failure is unknown. In this study, Lactobacillus probiotics did not result in a predictable change to the fecal microbiota or overall growth compared with placebo in these patients.
短肠综合征(SBS)患儿常面临吸收不良和生长发育迟缓的问题。肠道微生物群在肠道功能中起重要作用,已知SBS患儿的一些共生肠道微生物存在缺陷。增强肠道微生物群的一种策略是服用益生菌。然而,这种方法的疗效尚未得到充分证实。我们假设补充益生菌会导致补充细菌水平升高并改善生长。
已从肠外营养断奶但生长发育欠佳的SBS患儿被随机分为两组,一组每日接受益生菌(鼠李糖乳杆菌和约翰逊乳杆菌),另一组接受安慰剂,为期2个月。使用16S核糖体核糖核酸测序和定量聚合酶链反应比较两组每月粪便样本中的肠道微生物群。还比较了两组之间的生长情况。根据情况使用曼-惠特尼检验、克鲁斯卡尔-沃利斯检验和卡方检验完成统计分析。
18名SBS患儿完成了研究(每组9名)。两组中主要细菌家族均无显著变化。两组在基线或研究结束时,乳酸杆菌的相对丰度中位数无差异(分别为7.67对13.23,P = 0.523;1.93对15.8,P = 0.161)。在研究开始或结束时,两组体重和身长的z评分中位数无差异。
对于肠衰竭患儿,每日使用益生菌的疗效尚不清楚。在本研究中,与安慰剂相比,乳酸杆菌益生菌对这些患者的粪便微生物群或总体生长未产生可预测的变化。